Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Argus Health
US Department of Justice
Deloitte
Boehringer Ingelheim
AstraZeneca
Cipla
Queensland Health
Dow

Generated: June 17, 2018

DrugPatentWatch Database Preview

Recordati Rare Company Profile

« Back to Dashboard

What is the competitive landscape for RECORDATI RARE, and what generic alternatives to RECORDATI RARE drugs are available?

RECORDATI RARE has eight approved drugs.

There are three US patents protecting RECORDATI RARE drugs.

There are twelve patent family members on RECORDATI RARE drugs in six countries.

Summary for Recordati Rare
International Patents:12
US Patents:3
Tradenames:9
Ingredients:8
NDAs:8

Drugs and US Patents for Recordati Rare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recordati Rare INDOCIN indomethacin sodium INJECTABLE;INJECTION 018878-001 Jan 30, 1985 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-007 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up
Recordati Rare COSMEGEN dactinomycin INJECTABLE;INJECTION 050682-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-006 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Recordati Rare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982 RE28315 ➤ Sign Up
Recordati Rare TRANXENE clorazepate dipotassium TABLET;ORAL 017105-008 Approved Prior to Jan 1, 1982 RE28315 ➤ Sign Up
Recordati Rare TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-003 Approved Prior to Jan 1, 1982 RE28315 ➤ Sign Up
Recordati Rare TRANXENE SD clorazepate dipotassium TABLET;ORAL 017105-005 Approved Prior to Jan 1, 1982 RE28315 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RECORDATI RARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 10 mg/mL, 2 mL vial ➤ Subscribe 2010-10-01
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Accenture
Healthtrust
Cerilliant
Harvard Business School
Julphar
Johnson and Johnson
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.